ACLY and prostate cancer: Indeed, it has been shown that the inhibition of both the lactate transporter MCT1 and the key enzyme at the basis of lipid biosynthesis, i.e., the ATP citrate lyase (ACLY), strongly reduce the intracellular levels of acetyl-CoA, bringing the authors to the suggestion that lactate produced by cancer-associated fibroblasts (CAFs) represents the main source of acetyl-CoA in lipid-reprogrammed prostate cancer cells.